Literature DB >> 3406003

Biological classification of cell lines derived from human extra-cranial neural tumors.

C P Reynolds1, M M Tomayko, L Donner, L Helson, R C Seeger, T J Triche, G M Brodeur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3406003

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  34 in total

1.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

2.  p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.

Authors:  Shawki L Qasim; Laura Sierra; Ryan Shuck; Lyazat Kurenbekova; Tajhal D Patel; Kimal Rajapakshe; Jade Wulff; Kengo Nakahata; Ha Ram Kim; Yosef Landesman; T J Unger; Cristian Coarfa; Jason T Yustein
Journal:  Oncogene       Date:  2021-01-07       Impact factor: 9.867

3.  Notch pathway activation induces neuroblastoma tumor cell growth arrest.

Authors:  Peter E Zage; Riitta Nolo; Wendy Fang; John Stewart; Guillermo Garcia-Manero; Patrick A Zweidler-McKay
Journal:  Pediatr Blood Cancer       Date:  2011-07-08       Impact factor: 3.167

4.  Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Authors:  Andras Heczey; Daofeng Liu; Gengwen Tian; Amy N Courtney; Jie Wei; Ekaterina Marinova; Xiuhua Gao; Linjie Guo; Eric Yvon; John Hicks; Hao Liu; Gianpietro Dotti; Leonid S Metelitsa
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113

5.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Authors:  Liping Song; Tasnim Ara; Hong-Wei Wu; Chan-Wook Woo; C Patrick Reynolds; Robert C Seeger; Yves A DeClerck; Carol J Thiele; Richard Sposto; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

7.  Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Authors:  Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Authors:  Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

9.  The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc.

Authors:  Jun Li; Leo Kretzner
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

10.  Insulin-like growth factor-I is a serum component stimulating growth of human neuroblastoma.

Authors:  T W Burke; S Vuk-Pavlović
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-05       Impact factor: 2.416
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.